Short radiation with immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, chemotherapy, and an immunotherapy drug (Enlonstobart) for patients with a specific type of rectal cancer called pMMR. It aims to see if this approach can shrink tumors before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your cancer must be confirmed as colorectal adenocarcinoma with a pMMR biomarker (a type of tumor that has normal mismatch repair proteins)
- Your tumor must be located within 10 centimeters of the anal opening and be stage T3-4 or T1-2 with node involvement
- You must have good overall health (able to perform daily activities without major issues) and normal organ function (kidneys, liver, blood counts)
- You cannot have had previous radiation, targeted therapy, or immunotherapy for rectal cancer
- You must not have active autoimmune diseases or uncontrolled infections like HIV or hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
This trial tests a shorter course of radiation followed by a combination of chemotherapy, immunotherapy, and a targeted drug (bevacizumab) for locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink the tumor enough for surgery while avoiding more extensive radiation.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.